Welcome to LookChem.com Sign In|Join Free
  • or
(S)-tert-Butyl 3-(4-nitrophenoxy)pyrrolidine-1-carboxylate is a chemical compound that is widely utilized in the field of organic synthesis and drug development. It is an ester derived from the combination of pyrrolidine-1-carboxylic acid with (S)-tert-butyl 3-(4-nitrophenoxy)pyrrolidine-1-carboxylate. (S)-tert-Butyl 3-(4-nitrophenoxy)pyrrolidine-1-carboxylate features a pyrrolidine ring, a tert-butyl group, and a nitrophenyl group, which contribute to its unique chemical properties and reactivity. Its chiral nature makes it a valuable building block in the synthesis of pharmaceuticals and other biologically active compounds. Additionally, it has been investigated for its potential therapeutic effects in areas such as cancer treatment and cardiovascular diseases.

218944-23-1

Post Buying Request

218944-23-1 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

218944-23-1 Usage

Uses

Used in Pharmaceutical Industry:
(S)-tert-Butyl 3-(4-nitrophenoxy)pyrrolidine-1-carboxylate is used as a chiral building block for the synthesis of various pharmaceuticals and biologically active compounds. Its unique structure and reactivity allow for the creation of novel molecules with potential therapeutic applications.
Used in Organic Synthesis:
In the field of organic synthesis, (S)-tert-Butyl 3-(4-nitrophenoxy)pyrrolidine-1-carboxylate serves as a versatile intermediate for the development of new chemical entities. Its functional groups and chiral center enable the formation of a wide range of products with diverse applications.
Used in Cancer Treatment Research:
(S)-tert-Butyl 3-(4-nitrophenoxy)pyrrolidine-1-carboxylate is used as a potential therapeutic agent in cancer treatment research. Its unique chemical structure may offer new avenues for the development of targeted cancer therapies, potentially leading to more effective treatments with fewer side effects.
Used in Cardiovascular Disease Research:
(S)-tert-Butyl 3-(4-nitrophenoxy)pyrrolidine-1-carboxylate is also used in the study of cardiovascular diseases, where its potential therapeutic effects are being investigated. (S)-tert-Butyl 3-(4-nitrophenoxy)pyrrolidine-1-carboxylate's ability to interact with specific biological targets may contribute to the development of new treatments for various heart and blood vessel conditions.

Check Digit Verification of cas no

The CAS Registry Mumber 218944-23-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,1,8,9,4 and 4 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 218944-23:
(8*2)+(7*1)+(6*8)+(5*9)+(4*4)+(3*4)+(2*2)+(1*3)=151
151 % 10 = 1
So 218944-23-1 is a valid CAS Registry Number.

218944-23-1Relevant academic research and scientific papers

CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS

-

Paragraph 0300, (2015/03/13)

Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.

NAMPT inhibitors

-

Page/Page column 517, (2015/12/04)

Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.

INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE

-

Page/Page column 17, (2010/06/19)

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful

Inhibitors of Diacylglycerol Acyltransferase

-

Page/Page column 17, (2010/06/22)

Provided herein are amides containing at least a four ring structure, which are inhibitors of diacylglycerol acyltransferase and are useful for the treatment of diseases such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.

NEW COMPOUNDS

-

Page/Page column 26-27, (2008/12/06)

The present invention encompassescompounds of general formula (1) wherein R1 to R4 , X and n are defined as in claim 1, which are suitable for the treatment of ailments characterised byexcessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.

BISARYLUREA DERIVATIVES

-

Page/Page column 204-205, (2010/02/13)

The present invention relates to bisarylurea derivatives of formula (I), the use of the compounds of formula (I) as inhibitors of raf-kinase, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.

DIAMINOTHIAZOLES

-

Page/Page column 25, (2010/02/05)

The present invention is directed to novel diaminothiazoles of formula These compounds inhibit cyclin-dependent kinase 4 (Cdk4) and are selective against Cdk2 and Cdk1. These compounds and their pharmaceutically acceptable salts and esters have antiproliferative activity and are useful in the treatment or control of cancer, in particular solid tumors. This invention is also directed to pharmaceutical compositions containing such compounds and to methods of treating or controlling cancer, most particularly the treatment 6r control of breast, lung and colon and prostate tumors.

Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them

-

, (2008/06/13)

The invention relates to new derivatives of 2-(iminomethyl)amino-phenyl which are NO synthase inhibitors and can trap reactive oxygen species. These compounds can notably be used for the treatment of stroke, of neurodegenerative diseases and of ischemic or hemorragic cardiac or cerebral infarctions. These compounds include: N-{4-[({[4-(3,5-di-tert-butyl-4-hydroxyphenyl)-1,3-thiazol-2-yl]methyl}amino)methyl]phenyl}thiophene-2-carboximidamide; N-{3-[({[4-(3,5-di-tert-butyl-4-hydroxyphenyl)-1,3-thiazol-2-yl]methyl}amino)methyl]phenyl}thiophene-2-carboximidamide; N-(4-{[{[4-(3,5-di-tert-butyl-4-hydroxyphenyl)-1,3-thiazol-2-yl]methyl}(methyl)amino]methyl}phenyl)thiophene-2-carboximidamide; N-[3-({[3-(3,5-di-tert-butyl-4-hydroxyphenyl)propyl]amino}methyl)phenyl]thiophene-2-carboximidamide; N-(3-{[(3,5-di-tert-butyl-4-hydroxybenzyl)amino]methyl}phenyl)thiophene-2-carboximidamide; N-[3-({[2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethyl]amino}methyl)phenyl]thiophene-2-carboximidamide; N-[3-({[3-(4-hydroxy-3,5-diisopropylphenyl)propyl]amino}methyl)phenyl]thiophene-2-carboximidamide; N-(3-{[(4-hydroxy-3,5-diisopropylbenzyl)amino]methyl}phenyl) thiophene-2-carboximidamide; N-[3-({[2-(4-hydroxy-3,5-diisopropylphenyl)ethyl]amino}methyl)phenyl]thiophene-2-carboximidamide; N-2-(3,5-di-tert-butyl-4-hydroxybenzoyl)-N-1-(4-{[imino(thien-2-yl)methyl]amino}phenyl)-L-leucinamide; and pharmaceutically acceptable salts thereof.

New derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them

-

, (2008/06/13)

The invention relates to new derivatives of 2-(iminomethyl)amino-phenyl which are NO synthase inhibitors and can trap reactive oxygen species. These compounds can notably be used for the treatment of stroke, of neurodegenerative diseases and of ischemic or hemorragic cardiac or cerebral infarctions. These compounds include: N-{4-[({[4-(3,5-di-tert-butyl-4-hydroxyphenyl)-1,3-thiazol-2-yl]methyl}amino)methyl]phenyl}thiophene-2-carboximidamide; N-{3-[({[4-(3,5-di-tert-butyl-4-hydroxyphenyl)-1,3-thiazol-2-yl]methyl}amino)methyl]phenyl}thiophene-2-carboximidamide; N-(4-{[{[4-(3,5-di-tert-butyl-4-hydroxyphenyl)-1,3-thiazol-2-yl]methyl}(methyl)amino]methyl}phenyl)thiophene-2-carboximidamide; N-[3-({[3-(3,5-di-tert-butyl-4-hydroxyphenyl)propyl]amino}methyl) phenyl]thiophene-2-carboximidamide; N-(3-{[(3,5-di-tert-butyl-4-hydroxybenzyl)amino]methyl}phenyl) thiophene-2-carboximidamide; N-[3-({[2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethyl]amino}methyl) phenyl]thiophene-2-carboximidamide; N-[3-({[3-(4-hydroxy-3,5-diisopropylphenyl)propyl]amino}methyl) phenyl]thiophene-2-carboximidamide; N-(3-{[(4-hydroxy-3,5-diisopropylbenzyl)amino]methyl}phenyl) thiophene-2-carboximidamide; N-[3-({[2-(4-hydroxy-3,5-diisopropylphenyl)ethyl]amino}methyl) phenyl]thiophene-2-carboximidamide; N-2-(3,5-di-tert-butyl-4-hydroxybenzoyl)-N-1-(4-{[imino(thien-2-yl)methyl]amino}phenyl)-L-leucinamide; and pharmaceutically acceptable salts thereof.

Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them

-

Page column 102, (2008/06/13)

A compound selected from the group consisting of a compound of the formula wherein A is selected from the group consisting of and the other substituents are defined in the specification having an inhibitory activity of NO-synthase enzymes producing nitrogen mono-oxide and/or an activity which traps the reactive oxygen species.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 218944-23-1